ข่าวประชาสัมพันธ์ Cardiovascular Disease+Type 2 Diabetes

International Diabetes Federation (IDF) Global Survey Reveals 2 in 3 People With Type 2 Diabetes Have Cardiovascular Disease Risk Factors and/or Have Experienced a Cardiovascular Event

- Cardiovascular disease (CVD) is the leading cause of disability and death in people with type 2 diabetes[1] - Despite the high incidence, 1 in 4 people with type 2 diabetes have never discussed, or cannot recall discussing, CVD risk factors with a doctor[2] - First-ever global IDF survey investigating CVD awareness among people with type 2 diabetes received more than 12,000 responses in over 130 countries[2] To mark World Heart Day on 29 September, the International Diabetes Federation (IDF)

28 กันยายน 2561 15:00 น.

IDF and Novo Nordisk Launch First-ever Global Survey on Cardiovascular Disease Awareness among People with Type 2 Diabetes

- Taking Diabetes to Heart is a global online survey for people with type 2 diabetes to gain important insights about their awareness of cardiovascular disease (CVD) Globally,... ก.ย. 60

Mindray Expands Its Cardiac Biomarker Portfolio with Cutting-Edge hs-cTnI and NT-proBNP Assays, Empowering Enhanced Cardiovascular Diseases Care — Mindray (SZ... ต.ค. 66

เปลี่ยนมุมมอง ปรับความคิด เปลี่ยนชีวิตกับคุณหมอแอมป์ 5 ประเด็นสำคัญ กับโรคอ้วน ภัยร้ายที่ไม่ได้รับเชิญ — องค์การอนามัยโลก (WHO) ได้ให้นิยามของโรคอ้วน (Obe... มี.ค. 66

Possible Breakthrough in Cardiovascular Disease Diagnostics for Southeast Asia — Neuome Peptides Pte. Ltd., a Singapore-based company has established an a... ธ.ค. 65

สมาคมแพทย์โรคหัวใจแห่งประเทศไทยฯ และ ห้องปฏิบัติการตรวจวินิจฉัยโรคหัวใจ โรงพยาบาลจุฬาลงกรณ์ฯ ร่วมกับ ฟิลิปส์ ช่วยเหลือผู้ป่วยโรคหัวใจในพื้นที่ห่างไกล — โรคหัวใจและ... พ.ย. 65

เบาหวานเสี่ยงต่อโรคหัวใจอย่างไร — โรคเบาหวานเสี่ยงโรคหลอดเลือดหัวใจ (Cardiovascular Disease and Diabetes) ร้อยละ 68 ของผู้ป่วยเบาหวาน อายุ 65 ปีขึ้นไปจะ... พ.ย. 63

Addressing Social and Cultural Drivers of Type 2 Diabetes is Key to Its Treatment and Prevention

New research shows healthcare services and public health strategies aimed at reducing the burden of type 2 diabetes may prove ineffective, unless they address social and cultural factors.[1] Researchers... ต.ค. 61

World Heart Day: Nearly One in Five Deaths From Cardiovascular Disease are Caused by Air Pollution, a Total of 3 Million Deaths Globally Every Year

- On World Heart Day (WHD), 29 September 2018, World Heart Federation (WHF) is raising awareness of the link between poor air quality and cardiovascular... ก.ย. 61

Ozempic(R) Consistently Reduced the Risk of Major Cardiovascular Events Across Type 2 Diabetes Populations at High CV Risk Regardless of Prior CV Events at Baseline

Ozempic(R) (semaglutide) consistently reduced the risk of the composite outcome of time to first occurrence of non-fatal heart attack,... ส.ค. 61

Xultophy(R) Significantly Reduces Blood Sugar Levels, Body Weight and Risk of Hypoglycaemia for People With Type 2 Diabetes in Real-World Setting

- Results published in Diabetes, Obesity and Metabolism Newly published data from real-world European clinical practice has shown that Xultophy(R) (insulin... ธ.ค. 60

Ryzodeg(R) Significantly Reduces the Risk of Low Blood Sugar in People With Type 2 Diabetes who Fast During Ramadan

In people with type 2 diabetes who fast during Ramadan, Ryzodeg(R) (insulin degludec/insulin aspart) reduced the overall rate of low blood sugar (hypoglycaemia) including severe... ธ.ค. 60

Interim Results of First-Ever Global Survey Show People with Type 2 Diabetes Underestimate their Cardiovascular Risk

- Globally, cardiovascular disease (CVD) is the most common cause of death in people with type 2 diabetes[1] - 1 in 3 respondents considered themselves to be at low risk of CVD[2] - 1... ธ.ค. 60

Xultophy(R) Reported a Better Option than Basal-Bolus Insulin Therapy to Manage Type 2 Diabetes by Participants in the DUAL VII Clinical Trial

Once-daily Xultophy(R) (insulin degludec/liraglutide) was a better option to manage diabetes compared to multiple daily injections of insulin (basal-bolus... ธ.ค. 60

Xultophy(R) Offers Greater Blood Sugar and Body Weight Reductions in People With Type 2 Diabetes, Compared to IGlarLixi

New findings from an indirect comparison between Xultophy(R) and IGlarLixi published in the Journal of Medical Economics show that treatment with Xultophy(R) (insulin degludec... ธ.ค. 60

Merck and International Diabetes Federation Partner to Help Address Global Type 2 Diabetes Epidemic

The information contained in this release is not appropriate for audiences in the USA and Canada Focus on education and awareness-raising initiatives to facilitate prevention of type 2 diabetes... พ.ย. 60

Tresiba(R) Trial Shows that People with Type 2 Diabetes who Avoid Severe Hypoglycaemia have a Reduced Risk of Death

Symposium: S33 Novo Nordisk today announced new analyses from the multinational, double-blinded DEVOTE trial showing that people with type 2 diabetes who experience severe hypoglycaemia... ก.ย. 60

Ascensia Diabetes Care Launches Global Innovation Competition to Find Digital Solutions to Help Tackle the Epidemic of Type 2 Diabetes

Today, during the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD), Ascensia Diabetes Care announced the launch of the Ascensia... ก.ย. 60

Xultophy(R) Reduces Cardiovascular Risk Factors in People with Type 2 Diabetes

Oral Presentation 113 In people with type 2 diabetes, Xultophy(R) (insulin degludec/liraglutide) significantly reduced a number of risk factors associated with an increased risk of cardiovascular disease (CVD), compared to... ก.ย. 60

Victoza(R) Reduces the Risk of Major Cardiovascular Events in People with Type 2 Diabetes With or Without Prior Events

Oral Presentation 3909 A new analysis of the landmark LEADER trial shows that Victoza(R) (liraglutide) reduced the risk of major cardiovascular (CV) events in people with type 2... ส.ค. 60

Resverlogix Completes Dosing In ASSURE Clinical Trial

IVUS data will evaluate plaque regression in patients with high-risk Cardiovascular Disease TSX Exchange Symbol: RVX Resverlogix Corp. (TSX:RVX) today announced that it has completed dosing in ASSURE, a Phase 2b clinical trial evaluating RVX-208,... เม.ย. 56

Photo Release: KTC members make donation for children with congenital heart defect.

Mr. Dusit Ratchatasetanant(right), Executive Vice President Human Resources, “KTC” or Krungthai Card Public Company Limited, presented 80,441.50 Baht donation collected through the boxes at KTC Touch customer service... ต.ค. 55

Resverlogix's BET Protein Inhibitor RVX-208 Meets Primary Endpoint in SUSTAIN Clinical Trial in Patients With High Risk Cardiovascular Disease

Significant Increase in Functional HDL Persisted Throughout the 24-week Study Period Results from ASSURE Study Expected H1 2013, Using IVUS to Measure... ส.ค. 55

ASIANET: Worldwide Study to Evaluate New Approach

Worldwide Study to Evaluate New Approach to Preventing Cardiovascular Disease in Ace Inhibitor-Intolerant Patients - Largest Cardiovascular Protection Trial Ever Conducted in This Patient Population Will Parallel Landmark 'ONTARGET' Study - MILAN,... มิ.ย. 44

ASIANET: Landmark Worldwide 'ONTARGET' Study of Approximately 28,000 Patients

Landmark Worldwide 'ONTARGET' Study of Approximately 28,000 Patients to Evaluate the Role of a New Therapeutic Approach In Prevention Of Cardiovascular Disease Study at Up to 700 Sites Will Build On Landmark Hope Trial... มี.ค. 44